What the FDA labels say about taking them together
Aficamten and fluvoxamine
Aficamten's FDA label of December 16, 2025 names fluvoxamine in its drug interactions section; the fluvoxamine labels PlainMeds reads (2) do not name aficamten. The aficamten label: “Fluvoxamine; Clinical Impact; Fluvoxamine is a strong CYP2C19 inhibitor, weak to moderate CYP3A inhibitor, weak CYP2C9 inhibitor, and weak CYP2D6 inhibitor. …”
Check it at the source: the aficamten FDA label on DailyMed (effective December 16, 2025, Cytokinetics Inc.); the fluvoxamine FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.).
What does the aficamten label say about fluvoxamine?
Aficamten label, drug interactionsFluvoxamine; Clinical Impact; Fluvoxamine is a strong CYP2C19 inhibitor, weak to moderate CYP3A inhibitor, weak CYP2C9 inhibitor, and weak CYP2D6 inhibitor. Coadministration of fluvoxamine is predicted to increase aficamten exposure, which may increase the risk of developing heart failure due to systolic dysfunction.
Aficamten label, warnings and precautionsInitiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (e.g., fluconazole, voriconazole, fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction [see Contraindications (4), Warnings and Precautions (5.1), and Drug Interactions (7.1) ].
Source: FDA drug label (MYQORZO), Cytokinetics Inc., effective December 16, 2025 (SPL set fd778507-1274-4d1a-a659-5431d55c543a), via openFDA; the full label on DailyMed
What does the fluvoxamine label say about aficamten?
Fluvoxamine's label (effective June 27, 2026) and its 1 other brand-application label do not name aficamten in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Fluvoxamine maleate extended-release), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aficamten | Fluvoxamine | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $4.08 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once